Work

Long-term outcomes of pediatric AML in Tunisia: Lessons from 19 years of practice in Sousse

Year: 2025

Type: article

Abstract: Treating pediatric acute myeloid leukemia in resource-limited settings presents unique therapeutic challenges. This study shares 19 years of experience from a Tunisian center, focusing on practical treatment outcomes. Our pediatric AML cohort (n=68) shows 50% initial remission rates (75% with idarubicin vs 31% novantrone) and 9% induction mortality. Despite salvage therapy (43% CR2), 5-year survival remained at 33%, constrained by high relapse (53%) and limited transplant access (21%). These results highlight critical needs: optimized frontline therapy and expanded salvage options for refractory cases.

Source: Leukemia Research Reports

DOI: 10.1016/j.lrr.2025.100557

Authors: Donia Bouhoula, Haifa Regaieg, Hela Abroug, Nesrine Ben Sayed, Yossra Ben Youssef

Institutions: Hôpital Farhat Hached, University of Monastir, Hospital Fatuma Bourguiba Monastir

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,180